Marietta, GA7 Active Studies

Lung Cancer Clinical Trials in Marietta, GA

Find 7 actively recruiting lung cancer clinical trials in Marietta, GA. Connect with local research sites and explore new treatment options.

7
Active Trials
3
Sponsors
4,515
Enrolling

Recruiting Lung Cancer Studies in Marietta

RecruitingMarietta, GANCT06422143

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; M...

851 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingMarietta, GANCT06868277

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1....

830 participants
AstraZeneca
View Study Details
RecruitingMarietta, GANCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the co...

614 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingMarietta, GANCT05609968

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival ...

614 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingMarietta, GANCT06074588

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19de...

556 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingMarietta, GANCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...

530 participants
Bristol-Myers Squibb
View Study Details
RecruitingMarietta, GANCT06305754

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squ...

520 participants
Merck Sharp & Dohme LLC
View Study Details

About Lung Cancer Clinical Trials in Marietta

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 7 lung cancer clinical trials recruiting participants in Marietta, GA. These studies are seeking a combined 4,515 participants. Research is being sponsored by Merck Sharp & Dohme LLC, AstraZeneca, Bristol-Myers Squibb. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Marietta — FAQ

Are there lung cancer clinical trials in Marietta?

Yes, there are 7 lung cancer clinical trials currently recruiting in Marietta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Marietta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Marietta research site will contact you about next steps.

Are clinical trials in Marietta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Marietta studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 7 active trials in Marietta are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov